Medpace Holdings, INC Form 4 insider transactions

Medpace Holdings, Inc. President Jesse J. Geiger sold 21,503 shares of common stock at a weighted average price of $595.66 per share under a pre-arranged 10b5-1 plan.

Medpace Holdings Director Fred B. Davenport Jr. exercised stock options and subsequently sold a portion of his common stock holdings.

Medpace Holdings, Inc. President Jesse J. Geiger sold a total of 23,028 shares of common stock after exercising employee stock options.

Medpace Holdings' General Counsel, Stephen P. Ewald, exercised stock options and subsequently sold a portion of the acquired common stock.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, reported the sale of 2,000 shares of common stock for approximately $1.21 million.

Medpace Holdings, Inc. Director Robert O. Kraft converted 57 restricted stock units into common stock and disposed of 833 common shares on September 30, 2025.

Medpace Holdings Director Cornelius P. McCarthy III converted 49 restricted stock units into common stock on September 30, 2025, increasing his direct beneficial ownership to 10,246 shares.

Medpace Holdings, Inc. Director Brian T. Carley acquired 62 shares of common stock through the vesting of restricted stock units.

Medpace Holdings, Inc. Executive VP, Operations, Susan E. Burwig, exercised 10,000 employee stock options at $107.93 per share.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, sold 10,000 shares of common stock for approximately $4.8 million.

Medpace Holdings CEO August J. Troendle sold over 37,000 shares of common stock in pre-scheduled transactions under a 10b5-1 plan.

Medpace Holdings, Inc. CEO August J. Troendle sold 620 shares of common stock at $475 per share, executed under a pre-arranged trading plan.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, filed a Form 4 indicating a planned exercise of 10,000 stock options in August 2025.

A director at Medpace Holdings, Inc. reported the sale of 1,662 shares of common stock for approximately $465.04 per share.

Medpace Holdings, Inc.'s General Counsel, Stephen P. Ewald, reported a sale of 3,000 common shares and committed to disgorge profits due to a Section 16(b) short-swing trading violation.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, reported a pre-planned sale of 7,500 shares of common stock scheduled for July 28, 2025, at a weighted average price of $450.14 per share.

Medpace Holdings CEO and 10% owner, August J. Troendle, sold 48,487 shares of common stock for approximately $21.9 million in a pre-arranged transaction.

Medpace Holdings, Inc. President Jesse J. Geiger exercised stock options and subsequently sold a portion of the acquired common stock on July 24, 2025, as part of a pre-planned trading arrangement.

Medpace Holdings, Inc. CFO & Treasurer Kevin M. Brady exercised stock options and subsequently sold a portion of the acquired shares.

Medpace Holdings, Inc. Director Cornelius P. McCarthy III has scheduled the exercise of stock options to acquire 1,972 shares of common stock at $54.99 per share, effective July 22, 2025, under a Rule 10b5-1 plan.

Medpace Holdings, Inc. Director Cornelius P. McCarthy III exercised 4,500 stock options at $54.99 per share, increasing his direct beneficial ownership of common stock to 9,887 shares.

Medpace Holdings, Inc. Director Cornelius P. McCarthy III converted 50 restricted stock units into common stock on June 30, 2025, increasing his direct beneficial ownership of common stock.

Medpace Holdings, Inc. Director Robert O. Kraft converted 57 restricted stock units into common shares on June 30, 2025, as part of a pre-scheduled vesting.

Medpace Holdings, Inc. Director Brian T. Carley reported the acquisition of 62 shares of common stock through the conversion of restricted stock units, increasing his direct beneficial ownership to 26,157 shares.

Director Dani S. Zander acquired stock options in Medpace Holdings, Inc. on May 16, 2025.

Cornelius P. McCarthy III, a director of Medpace Holdings, Inc., acquired stock options exercisable for 1,224 shares of common stock.

Robert O. Kraft, a director of Medpace Holdings, Inc., acquired 1,224 stock options at a price of $305.66 on May 16, 2025, according to a Form 4 filing.

Director Femida H. Gwadry-Sridhar acquired stock options in Medpace Holdings, Inc. on May 16, 2025.

Director Fred B. Davenport Jr. of Medpace Holdings, Inc. reports the acquisition of stock options and changes in beneficial ownership of common stock.

Director Brian T. Carley of Medpace Holdings, Inc. reports the acquisition of stock options exercisable for 1,224 shares of common stock.